Table 1

Demographic and clinical data of the patients’ eyes treated with combined trabeculectomy and photodynamic therapy, using BCECF-AM as the photosensitising agent

Patient NoAgeSexDiagnosisSHPreop IOPPreop MedsOPPostop IOPLSLPostop complFU (days)FU-IOPRed from preop IOPPostop Meds
Abbreviations; AA = α2 agonist; ACG = angle closure glaucoma; AR = Axenfeld-Rieger-syndrome; B = hyphaema; BB = β blocker; CC = cyclocryocoagulation; CG = congenital glaucoma; CP = cyclophotocoagulation; DPOAG = dysgenetic primary open angle glaucoma; FU = follow up; FU-IOP = intraocular pressure at the latest follow up; H = hypotony; LSL = laser suture lysis; LTP = (argon) laser trabeculoplasty; IOP = intraocular pressure; M = miotic; Meds = medications; OP = date of operation (month/year); PEX = pseudoexfoliation glaucoma; PGA = prostaglandin analogue; PIGG = pigment dispersion glaucoma; POAG = primary open angle glaucoma; postop Compl = postoperative complications; preop IOP = preoperative intraocular pressure; Red from preop IOP = percentage of reduction from preop IOP to latest postop IOP; scar = failure due to scarring; SCI = systemic carboanhydrase inhibitor; SEC = secondary glaucoma; SH = surgical history; TCI = topical carboanhydrase inhibitor; TE = trabeculectomy; TEM = trabeculectomy combined with mitomycin C.
187MSEC40SCI; BB1/991340518−55%
273FPEX20SCI; TCI; PGA2/9923118TCI; BB; PGA
320MARTE, 2×CC, CP30SCI; BB; PGA1/991614scar
437FSECTO, CC, 4×CP45SCI; TCI; AA1/991414scar
543MSECTE24AA; BB; M; PGA1/995H93718−25%
684MSECTEM41SCI; BB; M; PGA3/997H9537−83%
782FPOAGCP31BB12/99146020BB
860MPOAG50SCI; BB; M3/999473scar
981FPEX2×TE40SCI; BB; PGA4/991733519BB; PGA
1082FPEX2×TE, CP50TCI; PGA4/993B63scar
1131MPOAG35SCI; PGA11/991014419−46%
1284FPOAG28SCI; AA; PGA11/9910×145920−29%
1369FACGTE20SCI; PGA10/99885212−40%
1460FDPOAGLTP, DS25M; TCI; BB; PGA12/9910×182914−44%
1524FDPOAGTE38SCI10/991H+Healon85016−58%
1621FCG3×CC38SCI; AA; PGA10/99856scar
1778FPEX18TCI; BB7/00636514TCI
1876FACG26SCI; AA; PGA1/0012×167018−31%
1961FPOAG2×CP, TE50AA; PGA5/00246919−62%
2020FDPOAG3×TE, TEM52SCI11/00221scar
2163FPOAG24BB; PGA3/0029013BB
2243FSEC3×TE, TEM26SCI; AA; PGA1/00614scar
2353FPOAG1×LTP36SCI; AA; PGA5/0014×165620BB
2453FPOAG30SCI; AA; PGA7/0010×260820BB
2545FPOAG48SCI; BB; AA5/00161217−65%
2654FPEX35SCI; M3/00172519−46%
2782FPOAGTE25TCI; AA; PGA10/0012×150420−20%
2882FPOAGTE32TCI; AA; PGA1/014×1172scar
2974FPOAGTE, LTP27AA; BB9/008×148518−33%
3031FSEC42SCI1/013030scar
3160FDPOAG20TCI; BB; PGA1/01742318−10%
3264MPOAG27SCI1/0112×122518−33%
3336MSECTEM31SCI; TCI; AA12/007308scar
3458FPOAGTE, CP19TCI; AA; PGA1/011841312−37%
3558FPOAGCP30AA; PGA3/01336512−60%
3660MPOAGTE24AA; PGA5/011213412−50%
3766MPOAG26TCI; BB; AA1/015×115914−46%
3873MPOAG30TCI; AA; PGA5/011026113−57%
3974MPOAG18M; AA; PGA2/015×151715−17%
4074MPOAG28M; AA; PGA2/0112×149814−50%
4138MPDG28M; BB; PGA5/01440717−39%
4275MPOAG21TCI10/011710416−24%